P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events

Overview of attention for article published in JACC, July 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs

twitter: 374 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 43 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 2 posts from 2 blogs.

P2Y₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease

Physician's Weekly, 12 Jul 2023

MONDAY, July 10, 2023 (HealthDay News) — For patients with coronary artery disease (CAD), P2Y12 inhibitor monotherapy is…

M-A | P2Y12 inhibitors show superior efficacy over aspirin for secondary prevention in CAD

SPECIALTIES, 11 Jul 2023

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events – Journal of the American College of…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.